Extending the Spectrum of Precompetitive Collaboration in Oncology Research

Extending the Spectrum of Precompetitive Collaboration in Oncology Research

by Erin Balogh, Margie Patlak, Sharyl J. Nass, Board on Health Care Services Staff, Institute of Medicine Staff

Browse books you can read free on Readfeed

No club is reading this yet — be the first to start one

Start a club free
About
"Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development. While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings."--Publisher's description.

Discuss Extending the Spectrum of Precompetitive Collaboration in Oncology Research with other readers

Join or start a book club for Extending the Spectrum of Precompetitive Collaboration in Oncology Research on Readfeed. Live chat, shared reading progress, and AI discussion questions — free to get started.

Frequently asked questions

How do I join a book club for Extending the Spectrum of Precompetitive Collaboration in Oncology Research?

Sign up free on Readfeed, then browse public clubs or start your own club with Extending the Spectrum of Precompetitive Collaboration in Oncology Research as the current read. Invite friends with a share link and discuss together with live chat and AI discussion questions.

Can I discuss Extending the Spectrum of Precompetitive Collaboration in Oncology Research with other readers online?

Yes. Readfeed book clubs let you chat live, share progress, and join discussions about Extending the Spectrum of Precompetitive Collaboration in Oncology Research with readers worldwide — whether your club is virtual, in-person, or hybrid.

Is Readfeed free?

Yes. Creating an account and joining book clubs is free. Sign up to find readers who love the same books and start discussing today.